Tech Company Financing Transactions
Molecular Insight Pharmaceuticals Funding Round
Molecular Insight Pharmaceuticals, based in Cambridge, raised $28 million from Siemens Venture Capital and Tudor Ventures.
Transaction Overview
Company Name
Announced On
4/21/2005
Transaction Type
Venture Equity
Amount
$28,000,000
Round
Series C
Investors
Siemens Venture Capital (Andrew Jay)
Proceeds Purpose
These funds allow us to move rapidly into a pivotal Phase 3 program with BMIPP for diagnosing acute ischemia, expand BMIPP's clinical development for other significant indications, and advance our targeted radiotherapeutic into human studies for the treatment of neuroendocrine tumors.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
160 Second Street
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Molecular Insight Pharmaceuticals is developing and commercializing innovative molecular imaging pharmaceuticals and targeted radiotherapeutics to diagnose and treat disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Scientific Officer
John Babich
VP - Manufacturing
Wendy Graham-Coco
VP - Regulatory Affairs
James Wachholz
Browse more venture capital transactions:
Prev: 4/20/2005: Intergis venture capital transaction
Next: 4/21/2005: T-RAM Semiconductor venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs